These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25345953)

  • 21. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
    Ahrén B; Schweizer A; Dejager S; Dunning BE; Nilsson PM; Persson M; Foley JE
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1236-43. PubMed ID: 19174497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.
    Pratley RE; Rosenstock J; Pi-Sunyer FX; Banerji MA; Schweizer A; Couturier A; Dejager S
    Diabetes Care; 2007 Dec; 30(12):3017-22. PubMed ID: 17878242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study.
    Rosales R; Abou Jaoude E; Al-Arouj M; Fawwad A; Orabi A; Shah P; DiTommaso S; Vaz J; Latif ZA
    Diabetes Obes Metab; 2015 Jun; 17(6):603-607. PubMed ID: 25586779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
    Chatterjee S; Chatterjee S
    J Diabetes; 2014 May; 6(3):237-42. PubMed ID: 23879210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
    Kozlovski P; Fonseca M; Mohan V; Lukashevich V; Odawara M; Paldánius PM; Kothny W
    Diabetes Obes Metab; 2017 Mar; 19(3):429-435. PubMed ID: 27943546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
    Al-Arouj M; Hassoun AA; Medlej R; Pathan MF; Shaltout I; Chawla MS; Hristoskova S; Ditommaso S; Kadwa MY
    Int J Clin Pract; 2013 Oct; 67(10):957-63. PubMed ID: 24001317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V; Schweizer A; Albrecht D; Baron MA; Chang I; Dejager S
    Diabetologia; 2007 Jun; 50(6):1148-55. PubMed ID: 17387446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
    Rosenstock J; Niggli M; Maldonado-Lutomirsky M
    Diabetes Obes Metab; 2009 Jun; 11(6):571-8. PubMed ID: 19383032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
    Dalla Man C; Bock G; Giesler PD; Serra DB; Ligueros Saylan M; Foley JE; Camilleri M; Toffolo G; Cobelli C; Rizza RA; Vella A
    Diabetes Care; 2009 Jan; 32(1):14-8. PubMed ID: 18931099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
    Haidinger M; Werzowa J; Voigt HC; Pleiner J; Stemer G; Hecking M; Döller D; Hörl WH; Weichhart T; Säemann MD
    Trials; 2010 Oct; 11():91. PubMed ID: 20925938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
    Suzuki L; Kanazawa A; Uzawa H; Osonoi Y; Masuyama A; Azuma K; Takeno K; Takayanagi N; Sato J; Someya Y; Komiya K; Goto H; Mita T; Ikeda F; Ogihara T; Shimizu T; Ohmura C; Saito M; Osonoi T; Watada H
    Expert Opin Pharmacother; 2017 Dec; 18(18):1921-1928. PubMed ID: 29141460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
    Dejager S; Razac S; Foley JE; Schweizer A
    Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.